These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33356370)

  • 1. Lp(a) (Lipoprotein[a]), an Exemplar for Precision Medicine: Insights From UK Biobank.
    Hopewell JC; Clarke R; Watkins H
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):475-477. PubMed ID: 33356370
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations.
    Dron JS; Wang M; Patel AP; Kartoun U; Ng K; Hegele RA; Khera AV
    Circ Genom Precis Med; 2021 Feb; 14(1):e003182. PubMed ID: 33522245
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications of the UK Biobank prognostic study for preventive cardiology.
    Jelinek M; Vale M
    Eur J Prev Cardiol; 2020 Jul; 27(10):1034-1035. PubMed ID: 31795760
    [No Abstract]   [Full Text] [Related]  

  • 4. Cholesterol Insights and Controversies From the UK Biobank Study.
    Mora S; Martin SS; Virani SS
    Circulation; 2019 Aug; 140(7):553-555. PubMed ID: 31403842
    [No Abstract]   [Full Text] [Related]  

  • 5. UK Biobank data on 500,000 people paves way to precision medicine.
    Nature; 2018 Oct; 562(7726):163-164. PubMed ID: 30365879
    [No Abstract]   [Full Text] [Related]  

  • 6. United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8.
    Caleyachetty R; Littlejohns T; Lacey B; Bešević J; Conroy M; Collins R; Allen N
    J Am Coll Cardiol; 2021 Jul; 78(1):56-65. PubMed ID: 34210415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of the UK biobank high impact papers in the era of precision medicine.
    Glynn P; Greenland P
    Eur J Epidemiol; 2020 Jan; 35(1):5-10. PubMed ID: 31993883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study.
    Naka KK; Bechlioullis A; Marini A; Sionis D; Vakalis K; Triantis G; Wilkins L; Rogus J; Kornman KS; Witztum JL; Doucette-Stamm L; Michalis LK; Tsimikas S
    J Clin Lipidol; 2018; 12(2):338-347. PubMed ID: 29310992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter by Enas and Varkey Regarding Article, "Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study".
    Enas EA; Varkey B
    Circulation; 2022 Feb; 145(5):e146. PubMed ID: 35100018
    [No Abstract]   [Full Text] [Related]  

  • 10. Response by Patel and Khera to Letter Regarding Article, "Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study".
    Patel AP; Khera AV
    Circulation; 2022 Feb; 145(5):e147-e148. PubMed ID: 35100017
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cardiovascular Health Measures With Cardiovascular Disease and Mortality in CKD: A UK Biobank Study.
    Geng T; Zhang YB; Lu Q; Wan Z; Pan A; Liu G
    Am J Kidney Dis; 2022 Dec; 80(6):805-807. PubMed ID: 35314249
    [No Abstract]   [Full Text] [Related]  

  • 13. Rare-variant collapsing analyses reveal novel risk genes for arterial and venous cardiovascular diseases in the UK biobank.
    Zöller B; Manderstedt E; Lind-Halldén C; Halldén C
    Thromb Res; 2023 Sep; 229():86-89. PubMed ID: 37421682
    [No Abstract]   [Full Text] [Related]  

  • 14. Human Cytomegalovirus and Risk of Incident Cardiovascular Disease in UK Biobank.
    Yates TA; Griffith GJ; Morris TT
    J Infect Dis; 2022 Apr; 225(7):1301-1302. PubMed ID: 35024849
    [No Abstract]   [Full Text] [Related]  

  • 15. Hormone use missing from UK Biobank cardiovascular disease study.
    Grant EC
    Heart; 2018 Jul; 104(14):1225. PubMed ID: 29945946
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting lipoprotein (a): an evolving therapeutic landscape.
    Man LC; Kelly E; Duffy D
    Curr Atheroscler Rep; 2015 May; 17(5):502. PubMed ID: 25736345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank".
    Thomaides-Brears H; Banerjee R; Banerjee A
    J Hepatol; 2024 Jan; 80(1):e24-e25. PubMed ID: 37821017
    [No Abstract]   [Full Text] [Related]  

  • 18. C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank.
    Morze J; Rynkiewicz A
    J Am Coll Cardiol; 2023 Nov; 82(20):e191-e192. PubMed ID: 37940236
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
    Nordestgaard BG; Langsted A
    J Lipid Res; 2016 Nov; 57(11):1953-1975. PubMed ID: 27677946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply: C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank.
    Burger PM; Visseren FLJ; Dorresteijn JAN
    J Am Coll Cardiol; 2023 Nov; 82(20):e193. PubMed ID: 37940237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.